Qiagen (NYSE:QGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Qiagen (NYSE:QGEN) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $51.17.

QGEN has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price objective on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Stifel Nicolaus reduced their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st.

Hedge Funds Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Qiagen by 0.8% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock valued at $151,526,000 after buying an additional 26,078 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Qiagen by 8.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after buying an additional 1,809,486 shares during the period. Optiver Holding B.V. boosted its holdings in shares of Qiagen by 1,211.4% in the fourth quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock worth $2,050,000 after buying an additional 43,612 shares during the period. Sei Investments Co. boosted its holdings in shares of Qiagen by 49.0% in the fourth quarter. Sei Investments Co. now owns 1,196,476 shares of the company’s stock worth $51,963,000 after buying an additional 393,553 shares during the period. Finally, Parkman Healthcare Partners LLC acquired a new position in shares of Qiagen in the fourth quarter worth about $10,858,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Down 0.1 %

NYSE:QGEN opened at $41.86 on Friday. Qiagen has a 12-month low of $34.74 and a 12-month high of $47.70. The firm has a market capitalization of $9.55 billion, a P/E ratio of 28.09, a P/E/G ratio of 3.48 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. The business has a 50 day simple moving average of $43.06 and a 200 day simple moving average of $43.64.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same quarter in the previous year, the firm posted $0.53 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. Equities research analysts predict that Qiagen will post 2.13 EPS for the current year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.